Investing.com – Biogen reported on Thursday fourth quarter that beat analysts’ forecasts and revenue that topped expectations.
Biogen announced earnings per share of $8.34 on revenue of $3.67B. Analysts polled by Investing.com anticipated EPS of $7.94 on revenue of $3.52B. That with comparison to EPS of $6.99 on revenue of $3.53B in the same period a year before. Biogen had reported EPS of $9.17 on revenue of $3.6B in the previous quarter. Analysts are expecting EPS of $7.89 and revenue of $3.42B in the upcoming quarter.
Biogen shares are down 4% from the beginning of the year and are trading at $282.52 , still down 16.63% from its 52 week high of $338.87 set on February 5, 2019. They are under-performing the Nasdaq 100 which is up 3.4% year to date.
Biogen follows other major Healthcare sector earnings this month
Biogen’s report follows an earnings beat by J&J on January 22, who reported EPS of $1.88 on revenue of $20.75B, compared to forecasts EPS of $1.87 on revenue of $20.8B.
Novartis ADR had beat expectations on Wednesday with fourth quarter EPS of $1.32 on revenue of $12.4B, compared to forecast for EPS of $1.31 on revenue of $12.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.